Skip to content
Review

Structural biology of the dengue virus NS2B-NS3 protease as a target for antiviral drug development.

Sep 2026 · Bioorganic chemistry (Print) · Vol 182, pp. 110485 · 0 citations · 124 references
Medicine

TL;DR

A comprehensive overview of the detailed structural information of the viral protease (NS2B/NS3) enzyme with the mechanistic role of this enzyme, and various inhibitors related to the NS2B/NS3 protease are highlighted.

Abstract

Dengue is the most common global problem in recent times, particularly in tropical and subtropical areas, yet antivirals for therapy or prophylaxis are lacking. Millions of people are affected by this dengue virus, but no proper medication is available yet to cure this disease. One polyprotein that is encoded by the DENV genome is converted into structural and non-structural proteins that are necessary for viral pathogenesis and replication. Among these, the non-structural protein complex NS2B-NS3 is essential for viral polyprotein processing, replication, and host innate immune response control. It acts as a trypsin-like serine protease. The NS2B/NS3 protease is a key enzyme involved in viral replication and serves as a major target for drug development against the dengue virus. The NS3 protease has a conserved catalytic triad (His-Asp-Ser), whereas NS2B serves as an essential cofactor that stabilizes the active conformation of the enzyme and aids in substrate recognition. By disrupting interferon signalling pathways, the NS2B-NS3 protease not only aids in viral replication but also makes immune evasion easier. The compound that inhibits the action of this enzyme could be pioneering in the antiviral drug discovery process. This article provides a comprehensive overview of the detailed structural information of the viral protease (NS2B/NS3) enzyme with the mechanistic role of this enzyme, and highlights various inhibitors related to the NS2B/NS3 protease. A more thorough comprehension of this protease could facilitate the logical development of potent antiviral medications to prevent dengue infection.

View source

Similar papers

Review Open access Aug 2026

Dengue Virus Molecular Targets and Antiviral Drug Development: Advances, Challenges and Therapeutic Perspectives

This narrative review critically analyses the principal molecular targets of DENV, including structural proteins (C, prM/M and E), nonstructural proteins (NS1–NS5) and host factors, with emphasis on the development of small‐molecule antivirals and an evaluation of their progress in pre‐clinical and clinical studies.

Aryane Lucia da Silva Aguiar De Oliveira, José Arion da Silva Moura, Pedro César de Souza et al. · 0 citations
Oct 2026

Production of a Versatile Pan-DENV NS5 Polyclonal Antibody and Structural Epitope Analysis of Immunogen Performance

Background: Dengue is a major mosquito-borne viral disease worldwide, with approximately 400 million infections reported annually and no fully effective antiviral treatments available. The non-structural protein NS5 is a promising antiviral target due to its critical role in viral RNA replication and host interactions....

Liliana Morales, C. Bueno Angarita, M. Calderón-Peláez et al. · 0 citations
Open access Sep 2026

Unveiling the antiviral mechanism of A4S7: a synthetic antimicrobial peptide targeting dengue and other mosquito-borne enveloped virus infections.

Dengue virus (DENV), an enveloped mosquito-borne flavivirus, is the causative agent of dengue and prevalent in tropical and subtropical regions. Severe cases can progress to dengue hemorrhagic fever or shock syndrome, posing significant public health challenges. In the absence of specific antiviral drugs, antimicrobial...

Ting-Chun Lin, Jeng-Wei Lu, Chia-Hsin Liu et al. · 0 citations
Review Open access Sep 2026

SARS-CoV-2 Drug-Resistant Mutations in Non-Structural Proteins

Evaluating the drug resistance mechanisms of multiple SARS-CoV-2 non-structural proteins, including the main protease and the RNA-dependent RNA polymerase, as well as PLPro, EndoU, and Mac1, which contribute to viral replication and counter host innate immune responses are discussed.

M. Shaw, A. Fehr · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.